Investors purchased shares of Abbott Laboratories (NYSE:ABT) on weakness during trading on Monday. $70.15 million flowed into the stock on the tick-up and $38.08 million flowed out of the stock on the tick-down, for a money net flow of $32.07 million into the stock. Of all stocks tracked, Abbott Laboratories had the 11th highest net in-flow for the day. Abbott Laboratories traded down ($0.19) for the day and closed at $41.68

Several research analysts have commented on the stock. Bank of America Corp. restated a “buy” rating on shares of Abbott Laboratories in a research report on Monday. Royal Bank Of Canada restated an “outperform” rating and issued a $48.00 target price on shares of Abbott Laboratories in a research report on Monday. Barclays PLC restated an “overweight” rating and issued a $48.00 target price on shares of Abbott Laboratories in a research report on Tuesday, July 12th. Jefferies Group upped their target price on shares of Abbott Laboratories from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, June 14th. Finally, TheStreet cut shares of Abbott Laboratories to a “hold” rating in a research report on Thursday, May 26th. Seven analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $46.83.

The company’s 50 day moving average is $43.36 and its 200 day moving average is $41.15. The stock has a market capitalization of $61.27 billion, a price-to-earnings ratio of 27.51 and a beta of 0.82.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, July 20th. The healthcare product maker reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.53 by $0.02. The firm earned $5.30 billion during the quarter, compared to analysts’ expectations of $5.24 billion. Abbott Laboratories had a net margin of 11.08% and a return on equity of 15.11%. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.52 EPS.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 15th. Stockholders of record on Friday, October 14th will be given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 2.50%. The ex-dividend date is Wednesday, October 12th. Abbott Laboratories’s dividend payout ratio is 68.87%.

In other news, EVP Hubert L. Allen sold 3,400 shares of Abbott Laboratories stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $37.14, for a total transaction of $126,276.00. Following the completion of the sale, the executive vice president now owns 91,857 shares in the company, valued at approximately $3,411,568.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Miles D. White purchased 242,547 shares of the stock in a transaction dated Monday, July 25th. The shares were acquired at an average price of $43.18 per share, with a total value of $10,473,179.46. Following the transaction, the chairman now owns 2,010,517 shares in the company, valued at $86,814,124.06. The disclosure for this purchase can be found here. Insiders own 0.26% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Abbott Laboratories by 1.6% in the second quarter. Vanguard Group Inc. now owns 97,826,407 shares of the healthcare product maker’s stock valued at $3,845,557,000 after buying an additional 1,535,735 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Abbott Laboratories by 16.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 36,209,595 shares of the healthcare product maker’s stock valued at $1,423,400,000 after buying an additional 5,115,232 shares during the last quarter. Bank of New York Mellon Corp raised its position in Abbott Laboratories by 1.3% in the second quarter. Bank of New York Mellon Corp now owns 29,256,692 shares of the healthcare product maker’s stock valued at $1,150,083,000 after buying an additional 376,446 shares during the last quarter. BlackRock Fund Advisors raised its position in Abbott Laboratories by 2.4% in the second quarter. BlackRock Fund Advisors now owns 22,778,032 shares of the healthcare product maker’s stock valued at $895,404,000 after buying an additional 538,002 shares during the last quarter. Finally, Jarislowsky Fraser Ltd raised its position in Abbott Laboratories by 780.3% in the second quarter. Jarislowsky Fraser Ltd now owns 18,800,322 shares of the healthcare product maker’s stock valued at $1,060,533,000 after buying an additional 16,664,605 shares during the last quarter. 73.12% of the stock is currently owned by institutional investors and hedge funds.

About Abbott Laboratories

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

5 Day Chart for NYSE:ABT

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.